Market closedADR
AstraZeneca/$AZN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Ticker
$AZN
Sector
Health Care
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Cambridge, United Kingdom
Employees
89,900
Website
AstraZeneca Metrics
BasicAdvanced
$242B
19.00
$4.12
0.15
$1.46
1.25%
Price and volume
Market cap
$242B
Beta
0.15
52-week high
$87.01
52-week low
$60.47
Average daily volume
4M
Dividend rate
$1.46
Financial strength
Current ratio
0.889
Quick ratio
0.69
Long term debt to equity
71.304
Total debt to equity
84.966
Dividend payout ratio (TTM)
69.29%
Interest coverage (TTM)
9.65%
Management effectiveness
Return on assets (TTM)
7.68%
Return on equity (TTM)
16.74%
Valuation
Price to earnings (TTM)
18.997
Price to revenue (TTM)
2.467
Price to book
4.69
Price to tangible book (TTM)
-8.83
Price to free cash flow (TTM)
17.207
Dividend yield (TTM)
1.86%
Forward dividend yield
1.25%
Growth
Revenue change (TTM)
10.45%
Earnings per share change (TTM)
4.27%
3-year revenue growth (CAGR)
18.50%
3-year earnings per share growth (CAGR)
12.79%
3-year dividend per share growth (CAGR)
1.98%
What the Analysts think about AstraZeneca
Analyst Ratings
Majority rating from 12 analysts.
AstraZeneca Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13B
5.45%
Net income
$2.2B
126.98%
Profit margin
17.18%
115.29%
AstraZeneca Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.08
$0.87
$0.73
$1.03
-
Expected
$0.95
$0.85
$0.79
$1.22
$1.22
Surprise
13.68%
2.96%
7.84%
15.80%
-
AstraZeneca News
AllArticlesVideos
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Proactive Investors·1 day ago
AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments
Reuters·1 day ago
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Barrons·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of $242B as of April 24, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 19 as of April 24, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of April 24, 2025, the dividend rate is $1.455 and the yield is 1.25%. AstraZeneca has a payout ratio of 69.29% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.